When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response

Shardule P. Shah¹, Sagar Lonial¹, and Lawrence H. Boise¹,²

Abstract

Multiple myeloma is a plasma cell malignancy with an estimated 26,850 new cases and 11,240 deaths in 2015 in the United States. Two main classes of agents are the mainstays of therapy—proteasome inhibitors (PI) and immunomodulatory drugs (IMiD). Other new targets are emerging rapidly, including monoclonal antibodies and histone deacetylase (HDAC) inhibitors. These therapeutic options have greatly improved overall survival, but currently only 15% to 20% of patients experience long-term progression-free survival or are cured. Therefore, improvement in treatment options is needed. One potential means of improving clinical options is to target resistance mechanisms for current agents. For example, eliminating the cytoprotective heat-shock response that protects myeloma cells from proteasome inhibition may enhance PI-based therapies. The transcription factor heat-shock factor 1 (HSF1) is the master regulator of the heat-shock response. HSF1 is vital in the proteotoxic stress response, and its activation is controlled by posttranslational modifications (PTM). This review details the mechanisms of HSF1 regulation and discusses leveraging that regulation to enhance PI activity. Mol Cancer Res; 13(8); 1163–73. ©2015 AACR.

Introduction

From 1971 to 1996, the overall survival rate for patients with multiple myeloma remained largely unchanged (1). Despite the use of alkylators, corticosteroids (dexamethasone and prednisone), and autologous bone marrow transplantation, little improvement was noted. Then, in 1999, thalidomide (in combination with dexamethasone) became the first new agent with major activity against multiple myeloma in 37 years (2). Thalidomide (Thalomid—2006 FDA approval) belongs to a class of structurally similar drugs known as immunomodulatory drugs (IMiD), along with lenalidomide (Revlimid—2006) and pomalidomide (Pomalyst—2013). IMiDs have helped to improve patient outcomes in recent years along with another major class of multiple myeloma agents: proteasome inhibitors (PI; ref. 3). The two FDA-approved PIs are bortezomib (Velcade—2003) and carfilzomib (Kyprolis—2012).

Proteasome Inhibition

The main effector in the ubiquitin–proteasome system (UPS) is the proteasome, a cytoplasmic protein complex responsible for protein degradation (4). The 26S proteasome is about 2,000 kilodaltons (kDa) in molecular mass and consists of one 20S protein subunit and two 19S regulatory cap subunits. Proteasomal degradation removes denatured, misfolded, damaged, or improperly translated proteins from cells. The UPS plays an essential homeostatic role in regulating intracellular protein concentration, as well as being a regulator involved in many cellular processes, including DNA repair, sodium channel function, regulation of immune and inflammatory responses, signal transduction, and cell-cycle progression (5).

Proteasome-mediated degradation is particularly vital for plasma cell quality control because of its role as a professional secretory cell that produces copious amounts of immunoglobulin in a constitutive manner. Therefore, proteasome inhibition can dramatically alter protein homeostasis leading to stress responses and if not resolved, apoptosis (6).

Bortezomib is a highly selective and reversible PI that has a boron atom that binds the β5 subunit (PSMB5)/chymotrypsin-like activity of the 26S proteasome (7). The proteasome has an ATP-dependent proteolytic activity, therefore, bortezomib’s targeting of β5 results in decrease or loss of proteasome function. Bortezomib was first reported as an anti-inflammatory agent for treating polyarthritis in 1998. Palombella and colleagues (8) used bortezomib as a means for inhibiting NF-kB activation by preventing proteasome-mediated degradation of IkB, an NF-kB negative regulator. For cancer, bortezomib was first tested in vitro by Adams and colleagues (9), in a 60 tumor cell line NCI screen, and was most potent in the prostate cancer cell line, PC-3. Cytotoxicity was speculated to be due to stabilization and dysregulation of cyclins, CDK inhibitors, tumor-suppressor proteins, IkB, and other proteins associated with cell-cycle progression. Hideshima and colleagues (10) published the first report on bortezomib in multiple myeloma cell lines and freshly isolated patient samples. In addition to the NF-κB mechanism described above, bortezomib was shown to alter cellular interactions and...
cytokine secretion in the bone marrow milieu to inhibit tumor cell growth, induce apoptosis, and overcome drug resistance. Mit- stades and colleagues (11) used high-dose bortezomib in the human multiple myeloma cell line, MM.1S to probe gene expression changes. These changes included a downregulation of growth/survival signaling pathways, upregulation of molecules implicated in proapoptotic cascades, and upregulation of ubiquitin–proteasome pathway members and heat-shock proteins (HSP). HSP27, 40, and 70 upregulation was seen as early as 2 hours after treatment. Bortezomib was FDA-approved in 2003 for patient use in large part due to the results of a phase II study of its use in relapsed/refractory multiple myeloma (12).

Up to this point, while gene expression profiling had been used to characterize the molecular sequelae of bortezomib treatment, mechanisms mediating anti-multiple myeloma activity had not yet been defined. Questions remained unanswered, including "Through what pathway(s) does PI induce apoptosis?" and "Is there a cellular event specific to plasma cells that can predict its effectiveness?" Hideshima and colleagues (13) began to scratch the surface of the bortezomib–cell biology connection by linking bortezomib, p53 phosphorylation, JNK activation, caspase-3 and 8 activation, inhibition of DNA damage repair, and cell death.

This study led to further investigation into the cell biology changes caused by bortezomib. However, what had not been looked at up to that point was specifically the plasma cell nature of a myeloma cell. Because of their role as immunoglobulin pro-ducers, plasma cells are heavily reliant on the unfolded protein response (UPR) for protein quality control (14). Lee and colleagues (15) suggested that UPR inhibition, through IRE1α or IPR transduction and splicing impairment of its downstream target, XBP1, plays a role in multiple myeloma PI-induced death. Our group proposed that PI could lead to an accumulation of misfolded proteins and an induction of terminal components of the UPR, including PERK, eIF-2α, ATF4, and its downstream target, CHOP (16). This was one of the first reports detailing how bortezomib was exploiting plasma cell biology, specifically immunoglobulin accumulation and terminal UPR activation, to induce apoptosis. Meister and colleagues (17) concluded that bortezomib-induced apoptosis is associated with the buildup of defective ribosomal products (DRIP) and other unfolded proteins in the endoplasmic reticulum (ER). Also, Bianchi and colleagues (18) determined that the balance between proteasome workload and degradative capacity represents a critical determinant of apoptotic sensitivity of multiple myeloma cell lines to PI. Furthermore, Ling and colleagues (19) have shown that low XBP1 levels predict poor response to bortezomib, both in vitro and in multiple myeloma patients, and ATF6 (a UPR transducer) expression correlates with bortezomib sensitivity. Leung-Hagesteijn and colleagues (20) proposed that the existence of PI-insensitive Xbp1s tumor progenitors within primary multiple myeloma tumors may produce class-effect PI resistance independent of drug identity. Mechanistically, Xbp1s suppression induces bortezomib resistance via decommitment to plasma cell maturation and immunoglobulin production, diminishing ER stress–asso-ciated cytotoxicity.

In addition to direct inhibition of the proteasome, PI-induced ER stress can also occur from aggresome formation and autophagy (21–23). Both are thought to be survival mechanisms used by cancer cells, and a recent study suggests that targeting the inte-grated networks of aggresome formation, proteasome, and autophagy may potentiate ER stress–mediated cell death pathways (21). However, one potential counter to PI effectiveness is the develop-ment of acquired mutations.

The direct target of bortezomib, PSMB5, is the most well-characterized mutation site (24). The PSMB5 mutation A49T has been shown to play in role in bortezomib resistance (25, 26). This mutation reduces bortezomib-induced apoptosis through the prevention of ubiquitinated protein accumulation and fatal ER stress in multiple myeloma. Despite this concern, no clinical evidence of an acquired proteasome subunit mutation has been published (25).

With the success of bortezomib in the clinic, second-generation PIs have been developed that have different activities, bioavail-ability (oral) and toxicity profiles. These agents have been the subject of intense preclinical and clinical studies. The first of these new inhibitors, carfilzomib, has now been FDA-approved for the treatment of relapsed/refractory multiple myeloma. Carfilzomib is an intravenous irreversible PI that binds to β5 with greater selectivity than bortezomib (27). NPI-0052 (marizomib), ONX 0912 (oprozomib), and MLN9708/2238 (ixazomib) are all in clinical trials (7, 27). Marizomib is being tested intravenously and oprozomib and ixazomib are being tested orally in multiple myeloma. Marizomib is a β-lactone-γ-lactam inhibitor that irreversibly binds β2 and β5 with high affinity and β1 with low affinity, and was granted "orphan drug" status by the FDA for multiple myeloma treatment. Phase I combination studies are being conducted using marizomib, pomalidomide, and dex- methasone in subjects with relapsed/refractory multiple myelo-ma (28). Oprozomib is an epoxyketone that irreversibly binds β5 with high affinity and was also recently granted "orphan drug" status by the FDA for multiple myeloma and Waldenstrom macroglobulinemia treatment. Ixazomib is a boric acid analogue that reversibly binds β5 with high affinity and at higher concentrations is able to inhibit β1 and β2. Two recently published companion reports from phase I oral ixazomib studies in relapsed/refractory multiple myeloma patients showed that 15% to 18% of patients achieved partial response or better with 76% reaching a state of stable disease or better in one of the studies (29, 30).

Continued improvement in current treatments and clinical trials, including those for second-generation PIs, has led some researchers to state that prolonged disease-free survival and a cure for a majority of patients are on the horizon (31). Improved disease-free survival can only occur if we can identify and target cellular resistance mechanisms. Resistance mechanisms, including HSP upregulation as part of the heat-shock response (HSR), can limit PI effectiveness. Therefore, inhibiting the HSR is a therapeutic opportunity for improving PI efficacy.

The HSR and HSPs

As mentioned above, HSP family members were reported amongst genes that were highly upregulated by bortezomib (11). The HSR is part of a cell's internal repair machinery and maintains homeostasis under stressful conditions, including infection, inflammation, exercise, exposure to toxins or pharma-cologic agents, starvation, or hypoxia (32). This response is carried out by HSPs, many of which act as chaperones assisting in protein folding and establishment of proper conformation while also preventing undesired protein aggregation. HSPs are categorized into five families: (i) HSP70 superfamily, (ii) DNAJ (HSP40) family, (iii) HSPB (small HSPs) family, (iv) HSP90/HSPC family,
and (v) Chaperonins and related genes (33). Although the cytoprotective HSR is desired in healthy cells, it could also protect cancer cells from bortezomib’s proapoptotic effects and is a potential resistance mechanism as demonstrated in bladder cancer cells (34). Zhang and colleagues (32) have published a detailed review of the connection between bortezomib and HSPs in multiple myeloma.

The cytoprotective nature of HSPs has stimulated preclinical testing and clinical trials of HSP90 and HSP70 inhibitors in multiple myeloma and other cancers. HSP90 inhibitors have been tested either alone or in combination with bortezomib and/or dexamethasone in multiple myeloma (35, 36). However, these studies to date have been disappointing and have yet to lead to an FDA-approved HSP90 inhibitor. Usmani and Chiosis (37) have comprehensively reviewed the promise and the results of these studies to date. HSP90 inhibitors have been tested either alone or in combination with bortezomib and/or dexamethasone in multiple myeloma (35, 36). However, there are conflicting views regarding which of these steps occurs first (65, 66). After trimerization and translocation, HSF1 binds to the heat-shock element (human HSE consensus sequence: nTTCnnGAAnnTTCn) in the promoter region of target HSPs. There are multiple HSE within each HSF promoter allowing for binding of multiple HSF1 trimers (67). In addition, there are interactions between HSF1–HSE and newly recruited activating molecules such as general transcription factors, for example, ATF1, Mediator complex, elongation factors, the chromatin remodeling complex SWI/SNF, histone-modifying proteins, for example, EP300/CREB, and RNA polymerase II (Pol II; refs. 54, 68). HSF1 transactivation includes continued binding to HSP70 and/or 40 complexes until shortly after HSF1 binds to HSE (63). HSP70 and/or 40 associate with HSF1 even when it is bound to DNA, and may continue to repress HSF1 until a secondary stimulus promotes its dissociation.

HSF binding can increase HSP gene transcription by over 100-fold (69). Transcription attenuation is mediated by a negative feedback loop. The newly translated HSPs themselves, most notably 70 and 40 and potentially 90, bind to the HSF1 transactivation domain (amino acids 440–529, near the HSF1 C-terminus; refs. 63, 70). Then, HSF1 detaches from the promoter region and leaves the nucleus, mediated, in part, by members of the 14-3-3 regulatory protein family. Preliminary evidence suggests that the HSF1 trimer is converted back to cytoplasmic monomers, but degradation also remains a possibility. Monomeric HSF1 complexes with HSP40, 70, and 90 to re-form the inactive tetramer.

**Regulation of HSF1 by Posttranslational Modifications**

Because HSF1 is present in an inactive form, activation is mediated through posttranslational modifications (PTM; Fig. 1). These include phosphorylation, sumoylation, and acetylation, in addition to 14-3-3 binding. Table 1 lists kinases and associated phosphorylation sites that have been shown or speculated to be involved with HSF1 dissociation (from the inert cytoplasmic heterotetramer), trimerization, nuclear translocation, HSF binding, transactivation, and HSR attenuation (71).

Soubrier and colleagues (72) have shown that PKCδ activates HSF1 by S333 phosphorylation in the stress responsive regulatory domain, potentially leading to dissociation of the repressive cytoplasmic HSF1–HSP90 interaction. HSF1-S333A, a mutant HSF1 lacking S333 phosphorylation, associated with endogenous HSP90 to a greater extent than did HSF1-S333E, a mutant HSF1 with constitutively active S333 phosphorylation (phosphomimetic). In addition, S333E was twice as efficient at activating HSF1 than S333A.

To date, no published phosphorylation events have been specifically linked to positive regulation of HSF1 trimerization.
HSF1 PTMs and activation life cycle. A. HSF1 activating (green) and repressive (red) PTMs are shown above. The bottom left box displays a PTM abbreviation key. Amino acids—K, lysine; S, serine; T, threonine. AD, activation domain; C, c-terminus; DBD, DNA-binding domain; LZ, leucine zipper domain; N, n-terminus; RD, regulatory domain. B. The HSF1 activation and attenuation cycle with associated PTMs is shown above. HSF1 forms a constitutively inactive heterotetramer with HSP 40, 70, and 90. (Continued on the following page.)

Figure 1.

Shah et al.

Mol Cancer Res; 13(8) August 2015

Molecular Cancer Research
Kim and colleagues (73) have shown that nuclear translocation is regulated by PLK1-mediated phospho(p)Serine(S)419, but has no role in HSF binding or transactivation. Also, Murshid and colleagues (74) demonstrated that shRNA against PKAα blocked S320 phosphorylation, preventing HSF1 nuclear translocation in addition to disrupting other activation events discussed below.

HSE binding and transactivation are distinct activation steps but are regulated by several common phosphorylation events. pS320 is critical for hsp70.1 promoter HSE binding, transactivation, and reversal of HSF1 nuclear export (74). CKII-mediated pT142 phosphorylation is also vital in HSE binding and transactivation (75). Soczewinski and colleagues have shown that a T142A mutant inhibits HSF1 binding to the nuclear receptor hSF1 and ultimately, HSP70 gene transcription. In addition, Holmberg and colleagues (76) observed that the molar ratio between CaMKII-mediated pS230 and pS320 blocks HSF1 transactivation. However, pS230 is not needed for either stress-induced HSF1 protein function, or the formation of nuclear stress bodies (the main site of accumulated HSF1, RNA Pol II, and other RNA-binding proteins in stressed cells).

Two related studies demonstrated that an early phosphorylation event, pS195, is critical for breakage of intramolecular interactions between leucine zipper domains (LZ) 2 and 3, an unmasking step required downstream for HSF1 transactivation (77, 78). In addition, the role of pS326 in transactivation has been widely published. Guettouche and colleagues (79) observed that pS326 facilitates HSF1 recruitment to HSE and stimulates transactivation under conditions of proteasome inhibition. Chou and colleagues (81) have shown that mTOR is responsible for pS326. Studies have also linked the MAPK–ERK pathway to pS326. However, the role of specific pathway members has not yet been resolved. For example, two studies have shown that MEK directly phosphorylates S326 (82, 83). However, Kim and colleagues (84) concluded that the MEK S326 is catalyzed by ERK1/2.

Sumoylation also positively regulates HSF1 activity. Hong and colleagues (85) observed K298-dependent HSF1 colocalization with SUMO-1 in nuclear stress bodies. K298 mutation resulted in a significant decrease in stress-induced transactivation in vitro. pS303 has been shown to stimulate K298 sumoylation by causing a conformation change that relieves the inhibitory effect of HSF1’s lone C-terminal leucine zipper (LZ4; ref. 86).

### Table 1. HSF1 kinases, their targets, and functional consequences

<table>
<thead>
<tr>
<th>Kinase</th>
<th>Amino acid target</th>
<th>Functional consequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMPKα</td>
<td>S121</td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
<tr>
<td>CAMKII</td>
<td>S230</td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
<tr>
<td>Casein kinase II</td>
<td>T142</td>
<td>Promotes HSE binding and transactivation</td>
</tr>
<tr>
<td>CDK1</td>
<td>S307, S326, S363</td>
<td>Represses HSE binding and transactivation and is required for 14-3-3ε binding (S307); promotes transactivation (S326) or may inhibit MEK phosphorylation (S326); may repress HSE binding and transactivation (S363)</td>
</tr>
<tr>
<td>ERK1/2</td>
<td>S307, S326, S363</td>
<td>Represses HSE binding and transactivation and is required for 14-3-3ε binding (S307); promotes transactivation (S326) or may inhibit MEK phosphorylation (S326); may repress HSE binding and transactivation (S363)</td>
</tr>
<tr>
<td>GSK3α</td>
<td>S303</td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
<tr>
<td>JNK</td>
<td>TAD, S307, S320, S363</td>
<td>Promotes transactivation and prolongs nuclear localization of HSF1 (TAD); represses HSE binding and transactivation (S307); promotes nuclear localization, HSE binding, transactivation, and may reverse nuclear export (S320); may repress HSE binding and transactivation (S363)</td>
</tr>
<tr>
<td>MAPKAP-K2</td>
<td>S211</td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
<tr>
<td>MEK</td>
<td>S326</td>
<td>Promotes HSE binding and transactivation</td>
</tr>
<tr>
<td>mTOR</td>
<td>S326</td>
<td>Promotes HSE binding and transactivation</td>
</tr>
<tr>
<td>PI3K</td>
<td>S326</td>
<td>Promotes nuclear localization, HSE binding, transactivation, and may reverse nuclear export (S320); may repress HSE binding and transactivation (S363)</td>
</tr>
<tr>
<td>PKAc</td>
<td>S320</td>
<td>Promotes nuclear localization, HSE binding, transactivation, and may reverse nuclear export (S320); may repress HSE binding and transactivation (S363)</td>
</tr>
<tr>
<td>PKCa, θ, ξ</td>
<td>S333, S363</td>
<td>Promotes nuclear localization, HSE binding, transactivation, and may reverse nuclear export (S320); may repress HSE binding and transactivation (S363)</td>
</tr>
<tr>
<td>PKCβ</td>
<td>S216, S419</td>
<td>Yeast only; promotes HSE binding when PKA activity is lowered by glucose deprivation</td>
</tr>
<tr>
<td>Rim15</td>
<td></td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
<tr>
<td>RSK2</td>
<td></td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
<tr>
<td>S112/MAPK7</td>
<td></td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
<tr>
<td>Snf1</td>
<td></td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
<tr>
<td>Snf1</td>
<td></td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
<tr>
<td>Yak1</td>
<td></td>
<td>Represses HSE binding and promotes HSF1 binding to HSP90</td>
</tr>
</tbody>
</table>
Interestingly, Raychaudhuri and colleagues (87) have shown that K298 is acetylated during the stress response in addition to K208. Catalyzed by the acetyltransferase EP300, K298 and K208 stabilize and prevent degradation of the HSF1-bound HSF1 trimmer. EP300 maintains HSF1 stability in a phosphorylation-independent manner (87). Ten potentially phosphorylated serines were replaced with alanines, yet HSF1 remained acetylation competent. Notably, HSF1 acetylation kinetics do not match those of transactivation (88). Stabilizing acetylation is delayed upon onset of HSF1 transactivation and persists when HSF1 activity and DNA binding have attenuated.

PTMs also mediate negative regulation. HSF1 is maintained in an inactive heterotetramer by constitutive phosphorylation at S121, S303, S307, and potentially S363. Liu and Thiele (89) have shown that the linker region enclosing pS121 might be a negative regulator of the monomer to trimer transition. Wang and colleagues (90) identified MAPKAP-K2 (MKII) as the pS121-specific kinase and noted that pS121 promotes cytoplasmic HSP90 binding to HSF1 to help maintain its inactive state. Another negative regulatory event is ERK1/2-mediated S307 phosphorylation, which has been shown to be a priming event for GSK3β-mediated phosphorylation of S303 (91). pS303 prevents HSF1 trimerization upon stress-induced activation. Thus, the priming requirement by pS307 provides a potential link between the MAPK cascade and HSF1.

However, a contrasting study by Batista-Nascimento and colleagues (92) has shown that when human HSF1 was expressed in yeast, Slt2 (MAPK7) phosphorylated S303 independently of both GSK3β and the pS307 priming event. The authors concluded that differences in HSF1 structure between in vitro and in vivo systems may help to explain why different kinases can mediate S303 phosphorylation under different conditions. Downstream of these phosphorylation events, Wang and colleagues (93) have shown that both GSK3β-mediated pS303 and ERK1-mediated pS307 are prerequisites for HSF1–14-3-3e binding. HSF1–14-3-3ε binding results in cytoplasmic HSF1 sequestration, specifically of the active, DNA-binding trimers. In addition, Chu and colleagues (94) demonstrated that pS363 is an early negative regulatory event that ultimately decreases HSF1’s transactivation capacity. pS303 and negative regulation through HSF1 PTMs may lead to treatments of multiple myeloma therapy.

HSF1 Inhibition in Cancer Treatment

Targeting HSF1 could be a more effective therapeutic strategy than pursuing individual HSP inhibition. However, developing transcription factor inhibitors is difficult for many reasons. One, transcription factors bind negatively charged DNA and therefore their exposed regions are largely positive. This requires that any inhibitor must be negatively charged, but charged molecules cannot freely diffuse across the cell membrane. In addition, the DNA–protein interface is large and developing effective small-molecule inhibitors is difficult. To cover the entirety of their binding pockets, a large molecule may have to be developed. Bioavailability may become a concern and promiscuous binding to other targets could cause side effects. Finally, screens for transcription factor inhibitors are less straightforward than those to other targets could cause side effects. Finally, screens for transcription factor inhibitors are less straightforward than those for kinase inhibitors, which are reliant on easier to detect processes such as ATP hydrolysis or phosphate transfer to a substrate. Despite these complexities, multiple HSF1 inhibitor screens have been performed and their various methods are described below.

Whitesell and Lindquist (99) detailed drug-like inhibitors of the HSF1-regulated HSR and concluded that all HSP induction inhibitors suffer from low potency and/or poor specificity. At the time of that publication, those inhibitors included quercetin and its prodrug QC12, NZ28, and its structural analogue emunin, KNK437, stresgenin B, and triptolide. Table 2 is an updated HSF1 inhibitor listing and Fig. 2 is an illustration of published inhibitor mechanisms. NZ28/emunin and triptolide will be discussed in detail below along with recently published inhibitors, cantharidin, 2,4-bis(4-hydroxybenzyl)phenol, KRBB11, and rohinitib. NZ28/emunin was discovered as the result of a high-throughput screen for small molecules that inhibit HSP induction (100).

The first step was performing a cell-based screen for inhibitors of

<table>
<thead>
<tr>
<th>Table 2. HSF1 inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Compound</strong></td>
</tr>
<tr>
<td>2,4-bis(4-hydroxybenzyl)phenol</td>
</tr>
<tr>
<td>Cantharidin</td>
</tr>
<tr>
<td>Emunin</td>
</tr>
<tr>
<td>KNK437</td>
</tr>
<tr>
<td>KRBB11</td>
</tr>
<tr>
<td>NZ28</td>
</tr>
<tr>
<td>QC12</td>
</tr>
<tr>
<td>Quercetin</td>
</tr>
<tr>
<td>Rohinitib</td>
</tr>
<tr>
<td>Stresgenin B</td>
</tr>
<tr>
<td>Triptolide</td>
</tr>
</tbody>
</table>
Multiple Myeloma, Proteosome Inhibition, and the Heat-Shock Response

A multiple myeloma therapeutic, its specific in vivo model in mice measuring tumor burden did not extend past 11 MM.1S to proteasome and HSP90 inhibitors without significant toxicity. However, its precise mechanism of HSP translation inhibition mechanism is unknown, and may involve events downstream of HSF1, leading to significant concerns over specificity (99).

Triptolide is a diterpenoid epoxide derived from Tripterygium wilfordii, a plant long used in Chinese medicine (101). Heimberger and colleagues (102) used triptolide to take advantage of a myeloma cell’s sensitivity to proteasome inhibition and subsequent reliance on the cytoprotective HSR. In MM.1S and INA-6 myeloma cell lines, triptolide in combination with bortezomib synergistically induced apoptosis. Although this is a promising result, concerns about the specificity of this agent exist. Triptolide interferes with NF-kB, NFAT, AP-1, and p53 activity, and inhibits global gene transcription by inducing RNA Pol II degradation and inhibiting the ATPase activity of the DNA helicase ERCC3 (103). In addition, the in vivo tumor model in mice measuring tumor burden did not extend past 11 days, which raises the question about the durability of triptolide’s in vivo effects (102). Although triptolide holds promise as a multiple myeloma therapeutic, its specific mechanisms must be better understood.

Yoon and colleagues (104) identified KRIBB11 from a synthetic chemical library screen. A heat-shock–dependent luciferase reporter plasmid was used to identify HSF1 inhibitors and KRIBB11 was chosen for further testing from an approximately 6,230 compound chemical bank. KRIBB11 abolished heat-shock–dependent HSP70 induction through HSF1 inhibition in colon carcinoma HCT-116 cells and also inhibited the growth of HCT-116 cells in a nude mouse xenograft regression model. KRIBB11 inhibited PI or HSP90 inhibitor-mediated HSP induction, indicating its potential use in combination therapy. Interestingly, while KRIBB11 does not inhibit heat-shock–induced recruitment of HSF1 to the hsp70 promoter, it does inhibit P-TEFb (positive transcription elongation factor, a heterodimer of CDK9 and cyclin T) recruitment. This study was able to show by affinity chromatography and competition assays that KRIBB11 specifically inhibits HSF1. In the competition assay, HSF2, HSP90, and CDK9, common HSF1 binding partners, were not detected, thus further strengthening the argument that KRIBB11 is HSF1 specific. In a separate study, Wiita and colleagues (105) combined KRIBB11 with low-dose bortezomib in MM.1S and saw an additive apoptotic effect. KRIBB11 shows HSF1 specificity and will be worth monitoring as it progresses through further preclinical studies.

Kim and colleagues (106) identified the blister beetle-derived compound cantharidin as an HSF1 inhibitor from a similar screen to the one used for KRIBB11. Cantharidin has been shown to have inhibitory effects on HSP70 and BAG3 expression in HCT-116 cells. Here, cantharidin blocked HSF1–dependent P-TEFb recruitment to the HSP70 promoter. Cantharidin demonstrated anticancer effects and an additive effect with bortezomib, but its HSF1 specificity is questionable. Cantharidin is known as a P2PA inhibitor (107). In addition, it has also been shown to be an activator of serine proteases in epidermal cells (108).

Another natural compound, 2,4-bis(4-hydroxybenzyl)phenol [referred to as (1) in the original publication and here as well], derived from the orchid Castodia elata, was identified from a screen using a luciferase reporter under the control of a HSE to find inhibitors of HSF1 activity in NC3-H460 human lung cancer cells (109). Similar to the previously mentioned studies, data from Yoon and colleagues indicate that (1) can lead to HSP suppression and an increase in apoptosis. The mechanism proposed is that (1) induces degradation of HSF1 through S326 dephosphorylation. However, HSF1 knockdown with siHSF1 þ (1) resulted in increased degradation compared to (1) alone, yet cell death with siHSF1 þ (1) is less than that of (1) by itself. Therefore, while this study points to a specific mechanism by which its compound works, more work is needed to confirm that observation.

Sanagata and colleagues (110) used a 300,000+ compound chemical screen to look for HSF1 inhibitors and found that the rocaglate, rocaglamide A, was the most potent and selective hit. Rocaglamide A inhibits translation initiation factor eIF4A, thus providing a link between HSF1 and protein translation flux. Rocaglate specificity for HSE reporter activity inhibition was demonstrated by stably transducing NIH3T3-HGL mouse embryonic fibroblasts with two constructs; one encoding a green fluorescent protein (GFP) driven by HSEs and the other encoding a red fluorescent protein (RFP) driven by a doxycycline-regulated control promoter. Rocaglates suppressed GFP but not RFP activity, whereas triptolide, quercetin, and KNK437 (among other previously reported HSF1 inhibitors), suppressed both GFP and RFP. An analogue, rohinitib (for Rocaglate Heat Shock), was found to be more potent than rocaglamide A while retaining similar selectivity and was used in vivo mouse studies. An M0-91 mouse myeloma xenograft model showed that rohinitib treatment resulted in significantly decreased tumor volume in addition to a dramatic reduction in HSPA8 mRNA. However, rocaglamide derivatives are known to inhibit NF-kB and therefore, rohinitib HSF1 specificity needs to be looked at in further detail (111). Regardless, investigation of the relationship between the ribosome, translation flux, and HSF1 will provide novel insight into targeting the biology of a cancer cell.

As noted earlier, the main difficulty of finding small-molecule transcription factor inhibitors stems from the size and complexity of the DNA–protein interface. In this regard, RNA aptamer technology may prove useful. RNA aptamers are small oligonucleotides that specifically bind to targets such as small proteins (112). RNA molecules share some common structural features with DNA, and RNA aptamers have been shown to target the DNA-binding domains of molecules such as NF-kB. Although aptamer technology is in its infancy as a therapeutic strategy, it can currently be used for drug target validation. For example, Salamanca, and colleagues (113), modified iRNAHSF1, a Drosophila RNA aptamer, to block HSE binding in HeLa cells and promote apoptosis.

In addition to direct HSF1 inhibition, targeting its activation by modulating PTMs is also a potential therapeutic strategy. HSF1 PTMs happen in all stages of activation and attenuation as previously described. The majority of published studies on HSF1 PTMs focus on phosphorylation events and their respective kinases. For example, the aforementioned study describing how HSP90 inhibition leads to nuclear HSF1 accumulation also showed that that accumulation was reduced by mTOR inhibition (53). Therefore, targeting kinases that activate HSF1 could be a simpler way of modulating targeting this pathway than developing HSF1 inhibitors.
Taken together, the findings described here show that HSF1 is involved in several cancers, including multiple myeloma. HSF1 has drawn interest as a biomarker though there are no known translocation groups or mutations associated with its activity (57, 114, 115). A broad variety of tumors, including carcinomas of the breast, cervix, colon, lung, pancreas, and prostate, as well as mesenchymal tumors such as meningioma, show increased HSF1 gene copy number, protein expression, or activation compared to their normal counterparts (56, 116). Dai and colleagues (117, 118) have shown a therapeutic window between cancer and normal cells by demonstrating that HSF1 depletion minimally affects normal cell viability, whereas cancer cells are strongly affected by HSF1 depletion. HSF1 inhibitors will likely play a role in treating a diverse range of malignancies, including multiple myeloma, because of HSF1's multifaceted role in promoting tumorigenesis (56, 57). We anticipate that one target multiple myeloma population will be those who are bortezomib-resistant. An HSF1 inhibitor could help unblock one potential bortezomib resistance mechanism and increase multiple myeloma apoptosis.

Although there is a demonstrated need for an HSF1 inhibitor, the future of HSF1 drug development will depend, in part, on the ability for therapeutic agents to be able to effectively and specifically target HSF1. Direct HSF1 inhibition has proven to be an elusive task, but the studies presented demonstrate progress. In addition to direct inhibition, new drugs could target HSF1 activation through PTM inhibition; for example, kinase or histone deacetylase (HDAC) inhibition or anti-SUMO therapies. Regardless of the mechanism, drugs should show the ability to work in tandem with current therapies, such as proteasome inhibition, because the majority of current induction therapy is based on combination and not single-agent treatments.

**Conclusions**

There is no universal cure for multiple myeloma, but recently developed therapies such as IMiDs and Pi's have dramatically increased patient survival. Bortezomib is effective in multiple myeloma therapy for a variety of reasons, including targeting its plasma cell biology. However, multiple myeloma cells counter bortezomib treatment by activating the HSR. This cytoprotective mechanism is regulated by the master transcription factor, HSF1. Developing a specific and effective HSF1 inhibitor has proven to be a challenge. While that aim is being pursued, a more practical approach is targeting HSF1 regulation. This strategy could have a dramatic impact on patient survival, especially when combined with current PI-based therapies, even beyond multiple myeloma. A genome-wide siRNA screen identified proteasome addiction as a vulnerability of basal-like triple-negative breast cancer (TNBC) cells (119). Multiple
myeloma, TNBC, and bladder cancer are three examples of malignancies whose patients could benefit from a therapeutic strategy of proteasome and HSF1 inhibition.

Disclosure of Potential Conflicts of Interest

S. Lonial is a consultant/advisory board member for Millennium, The Takeda Oncology Company, Celgene, Novartis, Bristol-Myers Squibb, Onyx Pharmaceuticals, and Janssen Pharmaceutical Companies, The Pharmaceutical Companies of Johnson & Johnson. L.H. Boise is a consultant/advisory board member for Onyx Pharmaceuticals and Novartis. No potential conflicts of interest was disclosed by the other author.

References


16. Kubiszkova L, Pour I, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors - molecular basis and current perspectives in multiple myelo-


26. Kubiszkova L, Pour I, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors - molecular basis and current perspectives in multiple myelo-


34. Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ, et al. Inhibition of inducible heat shock protein-70 (hsp72) enhances...

35. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a thera-

tumor activity against multiple myeloma by combination of KW-

37. Usmany ZM, Chiosi G. HSP90 inhibitors as therapy for multiple myelo-


44. Murphy ME. The HSP70 family and cancer. Carcinogenesis 2013;34:
1181–8.


47. Powers MV, Workman P. Dual targeting of HSC70 and HSP72 lines and inhibits paracrine tumour growth. Br J Haematol 2007;136:
796 enhances cytotoxicity triggered by bortezomib, heat shock protein
HSF1 drives a transcriptional program distinct from heat shock to support


Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response


Molecular Cancer Research

When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response

Shardule P. Shah, Sagar Lonial and Lawrence H. Boise


Updated version
Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-15-0135

Cited articles
This article cites 115 articles, 47 of which you can access for free at:
http://mcr.aacrjournals.org/content/13/8/1163.full#ref-list-1

Citing articles
This article has been cited by 14 HighWire-hosted articles. Access the articles at:
http://mcr.aacrjournals.org/content/13/8/1163.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mcr.aacrjournals.org/content/13/8/1163.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.